Poultry Anticoccidial Drugs Market Report Scope & Overview:

The Poultry Anticoccidial Drugs Market was valued at USD 1.46 Billion in 2025 and is expected to reach USD 2.22 Billion by 2035, growing at a CAGR of 4.28% from 2026-2035.

The Poultry Anticoccidial Drugs Market will see traction due to the heavy global burden of avian coccidiosis, rising poultry meat consumption, and the intensification of commercial broiler production. Coccidiosis, which is caused by various Eimeria species, is one of the greatest threats that poultry farms have faced in the form of enteric diseases, imposing an economic cost of about $12 billion per year. Coccidiosis is controlled through the use of ionophores and chemicals used in the feed, along with rotation and shuttle treatments that help to prevent resistance. The current trend that has been seen in terms of policies towards reducing the use of antibiotics has led to increased interest in vaccines, phytogenics, and immunomodulators. Rotation is a very important part of resistance management.

⮞In August 2024, Huvepharma received U.S. Food and Drug Administration approval for COXIDIN 90 (monensin) Type C medicated feeds. The product is approved as an aid in the prevention of coccidiosis in broiler chickens, laying hen replacement chickens, and layer breeder replacement chickens.

U.S. Poultry Anticoccidial Drugs Market Outlook

The U.S. Poultry Anticoccidial Drugs Market was valued at USD 398.24 Million in 2025 and is expected to reach USD 586.72 Million by 2035, growing at a CAGR of 3.94% from 2026-2035.

The U.S. Poultry Anticoccidial Drugs Market is expanding owing to the country's very large broiler industry, high standards of flock health management, and continuous product innovation by animal health companies. Rising consumer awareness about food safety and poultry product quality encourages producers to adopt preventive measures including anticoccidial programs. FDA approval pathways for medicated feed articles support a steady flow of new products, while the growth of no-antibiotics-ever production has increased use of live vaccines and natural alternatives. Elanco, Zoetis, Merck Animal Health, Phibro, and Huvepharma all compete actively across the country. Large integrated producers set most purchasing standards nationally.

⮞In July 2024, ZIVO Bioscience initiated a 42-day confirmatory study to validate the efficacy of its non-antibiotic, immune-modulating product for the prevention and treatment of coccidiosis in broiler chickens. The study reflects growing commercial interest in alternatives that avoid conventional antibiotic and ionophore compounds.

By Drug Class, Ionophores Lead, While Biologics Grow Fastest

Ionophores segment dominated the Poultry Anticoccidial Drugs Market in 2025, will continue to be the backbone of commercial coccidiosis prevention programs around the globe. Approved coccidiostats for use in poultry from the EU Register of Feed Additives include monensin, salinomycin, lasalocid, semduramicin, narasin, and maduramicin. Ionophores kill the parasite by disrupting ion transport, yet allowing for an immune response to form, providing long-term flock protection. Research has found that narasin was superior to salinomycin, and continued approvals from major suppliers confirm the dominance of the segment. The lower cost per bird is another factor contributing to the economic attractiveness of ionophores for most commercial poultry producers.

Biologics consist of live and attenuated anticoccidial vaccines and represent the fastest-growing drug class in response to the increasing antibiotic reduction measures and consumer demand for antibiotic-free poultry. Vaccines provide controlled exposure to Eimeria species, allowing the bird to develop natural immunity without constant medication. For instance, Vaxxilive Cocci 3 from Boehringer Ingelheim activates the bird’s innate immunity while causing minimal tissue damage. Vaccines help restore sensitivity to coccidiostats in rotation programs. The increasing popularity of no-antibiotics-ever and organic production methods should ensure strong growth of the vaccines segment. Application in hatcheries makes vaccine administration easier.

⮞In September 2025, China's Ministry of Agriculture and Rural Affairs renewed the import veterinary drug registration for a live-oocyst chicken coccidiosis vaccine manufactured by Intervet Inc., extending its registration through September 2030 and updating its approved quality standards and product labelling requirements.

By Type of Poultry, Broiler Chickens Lead, While Laying Chickens Grow Fastest

Broiler chickens segment dominated the Poultry Anticoccidial Drugs Market in 2025, due to the massive production of broilers globally and coccidiosis being extremely prevalent among intensively reared meat chickens. Intensively farmed broilers live in crowded floor space where Eimeria oocysts spread rapidly in litter. Hence, constant prevention with inclusion in feed is necessary. A study from 2024 found coccidiosis prevalence on broiler farms in Guangdong province of China as high as 98.88% at farm level. Due to the rapid production cycle and tough feed conversion targets, preventive medication becomes economically beneficial for broiler farmers, allowing the market segment to keep its leadership in terms of revenue globally. Broiler production continues to increase in most of the poultry-producing countries.

Laying chickens became the fastest-growing poultry species due to the global rise of egg production and increased productive lifespan of layers, hence increased risk of exposure to coccidiosis. Pullets need careful vaccination from coccidiosis before entering into egg-laying. Moreover, it is particularly convenient to use vaccination in layers due to long-life span and development of immunity. Expansion of cage-free and free range egg production leads to the rise of exposure to the disease. Also, approvals of regulatory authorities regarding layer breeder replacement chickens boost growth in the segment. The longer productive life of flocks entails higher needs in coccidiosis treatment per laying hen.

⮞In January 2026, Pilgrim’s announced plans to invest USD 1.3 billion in Mexico through 2030 to expand poultry production, targeting an additional 373,000 metric tonnes of chicken output. The planned expansion strengthens commercial broiler-production capacity and increases the importance of scalable flock-health management.

By Route of Administration, Feed Additives Lead, While Drinking Water Grows Fastest

The feed additives segment dominated the Poultry Anticoccidial Drugs Market in 2025, as in-feed medication remains the most practical way to deliver continuous preventive coccidiostat coverage across large commercial flocks. Type C medicated feeds allow uniform dosing without individual bird handling, which is essential at commercial scale. Integrated poultry producers typically contract feed mills to incorporate coccidiostats according to rotation and shuttle programs across the production cycle. Established regulatory frameworks for medicated feed articles in the United States and the European Union further reinforce this segment's leading share of market revenue. Feed mill infrastructure also supports consistent large-scale product delivery.

Drinking water administration is the fastest-growing route since it allows for quick therapeutic action once an outbreak of coccidiosis in the flock is discovered. Birds that are ill will not eat but continue drinking, making water-soluble medicines like sulphonamides and amprolium particularly effective in case of disease. Water administration also offers the advantage of changing doses rapidly without the need to re-formulate feed. Increasing use of automated water dosing systems in commercial poultry farms is boosting the efficacy of this route. With intensification in production systems putting more stress on quick response to outbreaks, the market for this segment is experiencing growth. Water administration also allows for treatment without interrupting the feed milling process at commercial farms.

⮞In July 2025, the European Commission adopted Implementing Regulation (EU) 2025/1419, updating the authorization framework for decoquinate feed additives, including Deccox and Avi-Deccox 60G, used in chickens for fattening. The regulatory update reinforces the role of approved medicated-feed products in commercial poultry coccidiosis prevention.

Regional Analysis

North America Poultry Anticoccidial Drugs Market Insights

North America accounted for approximately 32.46% of the Poultry Anticoccidial Drugs Market in 2025, the largest share among all regions, supported by a very large commercial poultry industry, advanced flock health management, and continuous product innovation. The United States generates most regional revenue, where coccidiosis causes significant economic losses through reduced productivity and higher mortality. Rising consumer awareness about food safety and poultry product quality encourages producers to maintain rigorous preventive programs. Leading suppliers including Elanco, Zoetis, Merck Animal Health, Phibro Animal Health, and Huvepharma continue developing innovative products for the region. Strong veterinary support networks further reinforce regional product adoption.

Canada is stepping up its involvement through government programs that enhance the animal health capacity. In March 2024, a program for funding worth up to USD 1.7 million was launched for promoting livestock health and disease preparedness, which will promote the uptake of current disease control measures and accessibility of drugs to small-scale farmers. In the case of Mexico, it is a market that is growing due to an increase in poultry production and protein consumption in the country. However, stringent rules for the use of antibiotics in food animals and increase in no-antibiotics ever production could change demand towards vaccines and natural products.

⮞In June 2026, Agriculture and Agri-Food Canada awarded up to CAD 892,122 to Amphoraxe Life Sciences through its AgriScience Program to develop antimicrobial-peptide formulations for poultry health. The project targets avian pathogenic E. coli and Salmonella, supporting innovation in alternative poultry-health interventions and strengthening the region’s animal-health research pipeline.

Europe Poultry Anticoccidial Drugs Market Insights

Europe continues to be a major regional market, supported by Germany, the United Kingdom, France, Italy, Spain, and Poland, which together form one of the world's largest poultry production bases. The European Union Register of Feed Additives governs which coccidiostats may be used, with monensin, salinomycin, lasalocid, semduramicin, and narasin approved for chickens, and a narrower list for turkeys. The EU's longstanding ban on antibiotic growth promoters and its farm-to-fork strategy for reducing antimicrobial use have accelerated interest in vaccines and phytogenic alternatives across the region. Producers increasingly combine both approaches within a single commercial broiler flock production cycle each season.

Germany, France, and Poland anchor regional demand through large broiler and layer operations, while the United Kingdom, Italy, and Spain contribute substantial production volumes. Huvepharma, headquartered in Bulgaria, and HIPRA in Spain are significant European suppliers of coccidiosis control products. Growing cage-free and free-range egg production across the region increases ground contact and coccidiosis pressure in layer flocks. However, the regulatory review of coccidiostats as feed additives and potential future restrictions create uncertainty for ionophore suppliers, encouraging investment in vaccine and natural product portfolios across European markets. Export requirements also strongly shape producer product selection and ingredient sourcing decisions across Europe.

⮞In March 2026, Germany’s Federal Statistical Office reported that egg production reached approximately 13.7 billion eggs in 2025, while the number of free-range laying hens increased 5.0% to 11.2 million. The expansion of alternative housing systems is relevant to layer-flock health management and coccidiosis prevention.

Asia-Pacific Poultry Anticoccidial Drugs Market Insights

Asia-Pacific is currently witnessing the highest growth rate in the Poultry Anticoccidial Drugs Market, anticipated to record a CAGR of around 5.46% during the forecast period from 2026 to 2035, driven by rapid expansion of commercial poultry production, rising protein consumption, and growing adoption of intensive farming systems. China is the largest market in the region, where research has documented coccidiosis prevalence of 98.88% at farm level and 87.06% at flock level in Guangdong province broiler operations. Rising scale and density of Chinese poultry production continue to sustain very high preventive medication demand. Government support for poultry sector modernization further reinforces this growth.

India is a key growth market, where coccidiosis prevalence in broilers fluctuates between 5% and 70% depending on temperature and humidity conditions, creating substantial seasonal demand for anticoccidial products. Rapid growth of the Indian broiler sector and expanding organized poultry integration support sustained market expansion. Southeast Asian countries including Thailand, Vietnam, and Indonesia are scaling commercial production for both domestic consumption and export. Japan, South Korea, and Australia contribute through advanced flock health programs and strict food safety standards governing veterinary medicine use in poultry. These markets favor premium products with strong residue control and comprehensive veterinary safety documentation records.

⮞In February 2026, India's Department of Animal Husbandry and Dairying published updated administrative guidance for vaccination under the Livestock Health and Disease Control programme, covering vaccine administration and reporting procedures. The initiative supports veterinary service delivery and disease-prevention infrastructure relevant to India's expanding poultry sector, although it is not specific to coccidiosis.

MEA & Latin America Poultry Anticoccidial Drugs Market Insights

The Middle East & Africa region represents a growing share of the Poultry Anticoccidial Drugs Market, with Gulf Cooperation Council countries leading regional demand and South Africa showing strong growth. Gulf states are investing in domestic poultry production to improve food security and reduce import dependence, creating new demand for flock health products. Hot and humid conditions in parts of the region increase coccidiosis pressure in commercial houses. South Africa anchors sub-Saharan demand through its established commercial poultry sector, although limited veterinary infrastructure constrains adoption across many other African markets. Rising local poultry investment may gradually improve this constrained situation.

Latin America is experiencing solid growth, with Brazil leading the region as one of the world's largest poultry producers and exporters, supported by highly integrated production systems and rigorous flock health programs. Export market requirements regarding residues and antibiotic use strongly influence Brazilian producers' product choices, encouraging vaccine adoption. Mexico and Argentina contribute significant demand through expanding domestic poultry industries. Colombia and Peru are also scaling commercial production. However, price sensitivity among smaller producers and reliance on lower-cost generic coccidiostats continue to limit premium product penetration across the region. Export-focused producers remain the main buyers of premium branded coccidiosis products.

⮞In October 2026, Saudi Arabia's Ministry of Environment, Water and Agriculture announced poultry-sector agreements worth approximately SAR 2.57 billion at the Middle East Poultry Expo. The agreements target production efficiency, supply-chain development and investment partnerships, supporting the expansion of domestic poultry production and associated animal-health requirements.

Market Dynamics

Growth Drivers: High Coccidiosis Burden and Poultry Production Growth

Growth in the Poultry Anticoccidial Drugs Market is primarily attributed to the severe global burden of avian coccidiosis, which costs the poultry industry an estimated USD 12 billion annually according to research published in Frontiers. Coccidiosis is among the most damaging enteric diseases in poultry farming, causing reduced feed conversion, impaired growth, and increased mortality. Meta-analysis published in Veterinary Medicine and Science identified Eimeria tenella as the most prevalent species infecting chickens. Addressing Eimeria impact is critical both for safeguarding poultry health and for sustaining the economic viability of commercial production. Subclinical infection also causes significant unmeasured flock performance losses.

Expanding global poultry production is further reinforcing market growth, as chicken remains the fastest-growing animal protein source worldwide. Rising populations, urbanization, and increasing disposable incomes in emerging economies are driving sustained demand for affordable poultry meat and eggs. Intensive production systems with high stocking densities create ideal conditions for Eimeria transmission through litter, making preventive medication essential rather than optional. Advancements in poultry healthcare, including better diagnostics, improved coccidiostat formulations, and structured rotation programs, continue to support consistent product demand across major producing regions. Expanding integration also standardizes flock health protocols across large vertically integrated poultry producers across major markets.

⮞In September 2026, the U.S. Department of Agriculture’s Economic Research Service updated its poultry-sector overview, reporting that total U.S. poultry sales reached USD 81.7 billion in 2025, compared with USD 70.3 billion in 2024. The scale of commercial poultry production reinforces the importance of preventive flock-health programs, including coccidiosis management.

Restraints: Drug Resistance and Antibiotic Reduction Policies

Growing drug resistance among Eimeria species remains a key factor limiting market growth. Decades of continuous coccidiostat use have reduced the effectiveness of several compounds, forcing producers to adopt rotation and shuttle programs that alternate drug classes between flocks and production phases. Resistance development shortens the commercial lifespan of individual products and increases the cost of maintaining effective control. Few genuinely novel anticoccidial compounds have reached the market in recent decades, as development costs and regulatory requirements for food animal products are high relative to expected returns for manufacturers. This limits the pipeline of genuinely new compounds entering the market.

Tightening antibiotic reduction policies are another limiting factor, as regulators and retailers push to lower antimicrobial use in food animal production. The European Union has banned antibiotic growth promoters and continues reviewing coccidiostat approvals, while no-antibiotics-ever programs expand across North American poultry supply chains. These shifts move demand away from conventional ionophore and chemical products toward fundamentally different approaches such as vaccines. The high cost associated with treatment options, particularly vaccines and premium natural alternatives, also constrains adoption among smaller producers in price-sensitive developing markets. Generic competition also compresses supplier margins further across most conventional anticoccidial drug product categories worldwide.

Opportunities: Vaccines and Natural Alternative Products

The expansion of anticoccidial vaccines creates a significant opportunity for manufacturers, as antibiotic-free and organic poultry production continues growing across developed markets. Live vaccines such as Boehringer Ingelheim's Vaxxilive Cocci 3 stimulate natural immunity while minimizing tissue damage, and vaccination programs also help restore flock sensitivity to coccidiostats when rotated with medication. Growing cage-free egg production and longer-lived layer flocks are particularly well suited to vaccination strategies. Companies that combine vaccines with diagnostic support and rotation program advisory services can build deeper, more durable relationships with integrated poultry producers. Hatchery-based delivery also simplifies vaccine administration at large commercial production scale.

At the same time, natural and non-antibiotic alternatives provide a major growth opportunity. Phytogenic products, saponin-based feed additives, and immune-modulating compounds are gaining commercial traction as producers seek antibiotic-free solutions. Orffa's Excential Sapphire Q, containing triterpenoid saponins and activated aluminosilicate, has demonstrated reduced coccidiosis pressure and improved broiler performance in U.S. trials. Amlan International's Phylox Feed offers another natural alternative to conventional anticoccidials. Rapid poultry industry expansion across Asia-Pacific, Latin America, and Africa also creates substantial demand for affordable coccidiosis control solutions. Local manufacturing and distribution partnerships can accelerate entry into several of these fast-growing emerging regional poultry production markets.

⮞In March 2025, researchers published a controlled broiler-chicken study in the journal Animals, evaluating a phytogenic supplement containing alkaloids and flavonoids against an experimental Eimeria challenge. The supplement reduced oocyst shedding relative to untreated challenged birds, supporting further investigation of plant-derived products as complementary coccidiosis-management options.

Poultry Anticoccidial Drugs Market Key Players

• Boehringer Ingelheim International GmbH

• Elanco Animal Health Incorporated

• Merck & Co., Inc. (MSD Animal Health)

• Zoetis Inc.

• Huvepharma AD

• Ceva Santé Animale

• HIPRA

• Phibro Animal Health Corporation

• Virbac SA

• Impextraco NV

• Biochem Zusatzstoffe GmbH

• Amlan International

• Orffa International Holding B.V.

• Kemin Industries, Inc.

• Alltech, Inc.

• Vetoquinol SA

• Dechra Pharmaceuticals Limited

• Bioproperties Pty Ltd

• Qilu Animal Health Products Co., Ltd.

• ZIVO Bioscience, Inc.

Poultry Anticoccidial Drugs Market Report Scope: